Heterosubtypic protection against pathogenic human and avian influenza viruses via In Vivo electroporation of synthetic consensus DNA antigens

PLoS ONE

Volumn 3, Issue 6, 2008, Pages

  Laddy, Dominick J ^a   Yan, Jian ^a   Kutzler, Michele ^a   Kobasa, Darwyn ^b   Kobinger, Gary P ^b,c   Khan, Amir S ^d   Greenhouse, Jack ^e   Sardesai, Niranjan Y ^d   Draghia Akli, Ruxandra ^d   Weiner, David B ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b PUBLIC HEALTH AGENCY OF CANADA   (Canada)

^c UNIVERSITY OF MANITOBA   (Canada)

^d VGX Pharmaceuticals Inc   (United States)

^e BIOQUAL INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DNA VACCINE; GAMMA INTERFERON; H5 HEMAGGLUTININ ANTIGEN; INFLUENZA VACCINE; NEUTRALIZING ANTIBODY; NUCLEOPROTEIN ANTIGEN; VIRUS SIALIDASE; ANTIGEN; DNA; PRIMER DNA; VIRUS ANTIBODY;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; AVIAN INFLUENZA; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; DISEASE COURSE; DRUG DELIVERY SYSTEM; ELECTROPORATION; FEMALE; FERRET; HEMAGGLUTINATION INHIBITION; HUMAN; IMMUNE RESPONSE; IMMUNOGENICITY; IN VIVO STUDY; INFLUENZA VIRUS A H5N1; MACACA; MALE; MORBIDITY; MORTALITY; MOUSE; NONHUMAN; PLASMID; PRIMATE; VACCINATION; VIRUS SHEDDING; VIRUS STRAIN; ANIMAL; BAGG ALBINO MOUSE; BIOSYNTHESIS; C57BL MOUSE; CROSS REACTION; ENZYME LINKED IMMUNOSORBENT ASSAY; IMMUNOLOGY; NUCLEOTIDE SEQUENCE; ORTHOMYXOVIRUS;

ANIMALIA; AVES; AVIAN INFLUENZA VIRUS; MACACA; MUS; MUSTELA; PRIMATES;

ANIMALS; ANTIBODIES, VIRAL; ANTIGENS; BASE SEQUENCE; CROSS REACTIONS; DNA; DNA PRIMERS; ELECTROPORATION; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FERRETS; HUMANS; MACACA MULATTA; MALE; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; ORTHOMYXOVIRIDAE; VACCINES, DNA;

EID: 49649094496     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0002517     Document Type: Article

References (34)

1. Chen R, Holmes EC (2006) Avian influenza virus exhibits rapid evolutionary dynamics. Mol Biol Evol 23: 2336-2341.
2. Robert G, Webster YG, MalikPeiris, ChenHonglin (2006) H5N1 Influenza Continues to Circulate and Change. Microbe 1: 559-565.
3. Forde GM (2005) Rapid-response vaccines-does DNA offer a solution? Nat Biotechnol 23: 1059-1062.
4. Bresson JL, Perronne C, Launay O, Gerdil C, Saville M, et al. (2006) Safety and immunogenicity of an inactivated split-virion influenza A/ Vietnam/1194/2004 (H5N1) vaccine: phase I randomised trial. Lancet 367: 1657-1664.
5. Lin J, Zhang J, Dong X, Fang H, Chen J, et al. (2006) Safety and immunogenicity of an inactivated adjuvanted whole-virion influenza A (H5N1) vaccine: a phase I randomised controlled trial. Lancet 368: 991-997.
6. Treanor JJ, Campbell JD, Zangwill KM, Rowe T, Wolff M (2006) Safety and immunogenicity of an inactivated subvirion influenza A (H5N1) vaccine. N Engl J Med 354: 1343-1351.
7. Draghia-Akli R, Khan AS, Brown PA, Pope MA, Wu L, et al. (2008) Parameters for DNA vaccination using adaptive constant-current electroporation in mouse and pig models. Vaccine.
8. Hirao LA, Wu L, Khan AS, Hokey DA, Yan J, et al. (2008) Combined effects of IL-12 and electroporation enhances the potency of DNA vaccination in macaques. Vaccine.
9. Hirao LA, Wu L, Khan AS, Satishchandran A, Draghia-Akli R, et al. (2008) Intradermal/subcutaneous immunization by electroporation improves plasmid vaccine delivery and potency in pigs and rhesus macaques. Vaccine 26: 440-448.
10. Epstein SL, Kong WP, Misplon JA, Lo CY, Tumpey TM, et al. (2005) Protection against multiple influenza A subtypes by vaccination with highly conserved nucleoprotein. Vaccine 23: 5404-5410.
11. Epstein SL, Tumpey TM, Misplon JA, Lo CY, Cooper LA, et al. (2002) DNA vaccine expressing conserved influenza virus proteins protective against H5N1 challenge infection in mice. Emerg Infect Dis 8: 796-801.
12. Roy S, Kobinger GP, Lin J, Figueredo J, Calcedo R, et al. (2007) Partial protection against H5N1 influenza in mice with a single dose of a chimpanzee adenovirus vector expressing nucleoprotein. Vaccine 25: 6845-6851.
13. Laddy DJ, Yan J, Corbitt N, Kobasa D, Kobinger GP, et al. (2007) Immunogenicity of novel consensus-based DNA vaccines against avian influenza. Vaccine 25: 2984-2989.
14. Kim JJ, Nottingham LK, Sin JI, Tsai A, Morrison L, et al. (1998) CD8 positive T cells influence antigen-specific immune responses through the expression of chemokines. J Clin Invest 102: 1112-1124.
15. Khan AS, Pope MA, Draghia-Akli R (2005) Highly efficient constant-current electroporation increases in vivo plasmid expression. DNA Cell Biol 24: 810-818.
16. Hebel H, Attra H, Khan A, Draghia-Akli R (2006) Successful parallel development and integration of a plasmid-based biologic, container/ closure system and electrokinetic delivery device. Vaccine 24: 4607-4614.
17. Kutzler MA, Robinson TM, Chattergoon MA, Choo DK, Choo AY, et al. (2005) Coimmunization with an optimized IL-15 plasmid results in enhanced function and longevity of CD8 T cells that are partially independent of CD4 T cell help. J Immunol 175: 112-123.
18. Stephenson I, Wood JM, Nicholson KG, Charlett A, Zambon MC (2004) Detection of anti-H5 responses in human sera by HI using horse erythrocytes following MF59-adjuvanted influenza A/Duck/Singapore/97 vaccine. Virus Res 103: 91-95.
19. Aihara H, Miyazaki J (1998) Gene transfer into muscle by electroporation in vivo. Nat Biotechnol 16: 867-870.
20. Babiuk S, Baca-Estrada ME, Foldvari M, Storms M, Rabussay D, et al. (2002) Electroporation improves the efficacy of DNA vaccines in large animals. Vaccine 20: 3399-3408.
21. Kadowaki S, Chen Z, Asanuma H, Aizawa C, Kurata T, et al. (2000) Protection against influenza virus infection in mice immunized by administration of hemagglutinin-expressing DNAs with electroporation. Vaccine 18: 2779-2788.
22. Otten G, Schaefer M, Doe B, Liu H, Srivastava I, et al. (2004) Enhancement of DNA vaccine potency in rhesus macaques by electroporation. Vaccine 22: 2489-2493.
23. Widera G, Austin M, Rabussay D, Goldbeck C, Barnett SW, et al. (2000) Increased DNA vaccine delivery and immunogenicity by electroporation in vivo. J Immunol 164: 4635-4640.
24. Zucchelli S, Capone S, Fattori E, Folgori A, Di Marco A, et al. (2000) Enhancing B- and T-cell immune response to a hepatitis C virus E2 DNA vaccine by intramuscular electrical gene transfer. J Virol 74: 11598-11607.
25. Brown DM, Dilzer AM, Meents DL, Swain SL (2006) CD4 T cell-mediated protection from lethal influenza: perforin and antibody-mediated mechanisms give a one-two punch. J Immunol 177: 2888-2898.
26. Epstein SL, Stack A, Misplon JA, Lo CY, Mostowski H, et al. (2000) Vaccination with DNA encoding internal proteins of influenza virus does not require CD8(+) cytotoxic T lymphocytes: either CD4(+) or CD8(+) T cells can promote survival and recovery after challenge. Int Immunol 12: 91-101.
27. Kreijtz JH, Bodewes R, van Amerongen G, Kuiken T, Fouchier RA, et al. (2007) Primary influenza A virus infection induces cross-protective immunity against a lethal infection with a heterosubtypic virus strain in mice. Vaccine 25: 612-620.
28. Thomas PG, Keating R, Hulse-Post DJ, Doherty PC (2006) Cell-mediated protection in influenza infection. Emerg Infect Dis 12: 48-54.
29. Renegar KB (1992) Influenza virus infections and immunity: a review of human and animal models. Lab Anim Sci 42: 222-232.
30. Laddy DJ, Weiner DB (2006) From plasmids to protection: a review of DNA vaccines against infectious diseases. Int Rev Immunol 25: 99-123.
31. Krohn K, Stanescu I, Blazevic V, Vesikari T, Ranki A, et al. (2005) A DNA HIV-1 vaccine based on a fusion gene expressing non-structural and structural genes of consensus sequence of the A-C subtypes and the ancestor sequence of the F-H subtypes. Preclinical and clinical studies. Microbes Infect 7: 1405-1413.
32. Malm M, Rollman E, Ustav M, Hinkula J, Krohn K, et al. (2005) Cross-clade protection induced by human immunodeficiency virus-1 DNA immunogens expressing consensus sequences of multiple genes and epitopes from subtypes A, B, C, and FGH. Viral Immunol 18: 678-688.
33. Weaver EA, Lu Z, Camacho ZT, Moukdar F, Liao HX, et al. (2006) Cross-subtype T-cell immune responses induced by a human immunodeficiency virus type 1 group m consensus env immunogen. J Virol 80: 6745-6756.
34. Yan J, Yoon H, Kumar S, Ramanathan M, Corbitt N, et al. (2006) Enhanced Diversity and Magnitude of Cellular Immune Responses Elicited by a Novel Engineered HIV-1 Subtype B Consensus-based Envelope DNA Vaccine. Molecular Therapy.